Pacific Edge Secures Singapore General Hospital Deal for Cxbladder Testing

Pacific Edge secures landmark Singapore General Hospital partnership

Pacific Edge (ASX: PEB) has signed a service agreement with Singapore General Hospital (SGH) for Cxbladder testing, marking a significant milestone in the company’s Asia Pacific expansion strategy. SGH, Singapore’s largest and oldest hospital serving more than 1 million patients annually, can now order Cxbladder Triage, Triage Plus (for hematuria evaluation), and Cxbladder Monitor (for bladder cancer recurrence surveillance).

The Pacific Edge Singapore Hospital Partnership positions the company to leverage SGH’s reputation as a regional standard-setter for healthcare. As SGH physicians and clinicians gain familiarity with the testing platform, Pacific Edge aims to use this institutional foothold to accelerate adoption discussions with other Asia Pacific hospitals and clinical networks.

What is Cxbladder and why does it matter?

Cxbladder is a suite of non-invasive genomic urine tests for bladder cancer detection and monitoring. Unlike traditional cystoscopy (an invasive camera procedure inserted through the urethra), Cxbladder uses genetic markers in urine to assess cancer risk, helping patients avoid unnecessary invasive procedures.

The platform has significant clinical validation. Cxbladder Triage is included in the American Urological Association (AUA) Microhematuria Guideline with Grade A evidence, supported by the STRATA randomised controlled trial, the first ever RCT of a urine biomarker. This guideline inclusion provides structural support for clinical adoption as urologists align their practice with recommended standards.

Pacific Edge offers three Cxbladder products:

1. Cxbladder Triage: Initial risk stratification for hematuria patients (blood in urine)
2. Cxbladder Triage Plus: Next-generation multi-modal test combining RNA and DNA analysis with improved performance characteristics
3. Cxbladder Monitor: Surveillance tool for bladder cancer recurrence in patients already diagnosed

For investors, the guideline inclusion and peer-reviewed validation reduce commercial adoption barriers. The tests address a genuine clinical need while delivering economic benefits for public healthcare systems, which must manage costs while maintaining quality patient care.

How will SGH implement Cxbladder testing?

Singapore General Hospital has outlined a focused clinical implementation strategy. Microhematuria patients will be offered Triage Plus, while lower-risk non-muscle invasive bladder cancer (NMIBC) patients on surveillance will be offered Monitor as an alternative to reduce cystoscopy frequency.

The payment model may require patients to pay for the tests directly, giving them choice between traditional cystoscopy or Cxbladder testing. Initial monthly volumes are expected to be modest as clinical teams become familiar with the platform and build confidence in the results.

Implementation details:

• Microhematuria patients → Triage Plus
• Lower-risk NMIBC surveillance patients → Monitor option to reduce cystoscopy frequency
• Patient choice model between cystoscopy and Cxbladder

The patient-pay model demonstrates real-world commercial viability in public healthcare systems. While the gradual adoption curve means near-term revenue contribution will build slowly, this realistic approach allows clinical teams to integrate Cxbladder into workflows without disrupting established protocols.

SGH’s regional influence

SGH’s role extends beyond Singapore. The hospital sets clinical standards across the Asia Pacific region, making this partnership strategically valuable as a reference site for other institutions. Pacific Edge’s strategy explicitly leverages SGH’s influence to drive broader regional adoption.

Dr Peter Meintjes, Chief Executive Officer, Pacific Edge

“We are working closely with SGH, recognizing the important role the hospital and its clinicians play in driving clinical practice change across the country and the entire Asia Pacific region.”

Success at SGH could accelerate partnership discussions with other Asia Pacific hospitals. Regional clinicians often monitor leading institutions for evidence of successful implementation before committing to new diagnostic platforms, making SGH adoption a potential catalyst for broader penetration.

Cxbladder’s established evidence base

Pacific Edge has built substantial clinical validation for its testing platform. The recent publication of the DRIVE study in the Journal of Urologic Oncology provides independent clinical validation for Triage Plus, while the STRATA randomised controlled trial supports Triage’s Grade A guideline inclusion. The broader evidence portfolio spans more than 25 peer-reviewed publications and over 20 years of research.

This depth of clinical evidence reduces adoption barriers for hospitals and physicians. Guideline inclusion provides a structural tailwind as clinicians align their practice with AUA recommendations, while peer-reviewed publications address concerns about test performance and reliability.

Commercial footprint context

The SGH partnership adds institutional depth to Pacific Edge’s existing commercial operations:

• US: More than 5,000 urologists have ordered over 130,000 tests
• New Zealand: Accessible to around 70% of the population via public healthcare, plus direct online purchase option
• Asia Pacific: Triage Plus available throughout the region to Australian, New Zealand and Southeast Asian customers

The partnership transforms Pacific Edge’s Asia Pacific strategy from customer-by-customer sales to institutional adoption. SGH represents the type of anchor customer that validates the platform for other regional hospitals considering Cxbladder implementation.

What comes next for Pacific Edge

Pacific Edge is seeking to leverage SGH success with other regional hospitals and clinicians. The partnership serves as proof-of-concept for broader Asia Pacific penetration, demonstrating that Cxbladder can integrate into government-funded hospital systems with patient-pay models.

Volumes will build gradually as clinical familiarity grows. Early-stage adoption requires physicians to trust the test results, understand how to interpret them, and integrate them into clinical workflows. This learning curve means the partnership’s financial impact will emerge over quarters rather than weeks.

For investors, SGH provides validation and a template for regional expansion. Monitoring adoption metrics and subsequent partnership announcements will indicate whether the Pacific Edge Singapore Hospital Partnership accelerates Asia Pacific momentum or requires extended market development.

Want the Next Biotech Breakthrough in Your Inbox?

Join 20,000+ investors getting FREE ASX biotech and healthcare news delivered within minutes of release, complete with expert analysis. Get breaking announcements and in-depth coverage before the market moves—click the “Free Alerts” button at Big News Blast to start receiving real-time alerts the moment companies like Pacific Edge make major announcements.